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Objectives The aim of this study was to evaluate late safety and efﬁcacy outcomes among patients
enrolled in clinical trials comparing Endeavor zotarolimus-eluting stents (E-ZES) (Medtronic, Inc.,
Santa Rosa, California) with ﬁrst-generation drug-eluting stents (DES) and bare-metal stents (BMS).
Background Despite demonstration of higher angiographic luminal loss and restenosis with E-ZES
compared with alternative DES, whether differences in these early angiographic measures translate
into more disparate late clinical events is uncertain.
Methods Among 3,616 patients undergoing percutaneous coronary revascularization in 5 registration
trials, late safety and efﬁcacy events were compared between E-ZES (n  2,132) versus sirolimus- or
paclitaxel-eluting stents (n  888) or BMS (n  596).
Results Compared with a parallel cohort of patients treated with ﬁrst-generation DES and BMS,
5-year rates of cardiac death/myocardial infarction (MI) (5.8% vs. 8.8% DES, p  0.003; vs. 8.4% BMS,
p  0.02) and major adverse cardiac events (16.1% vs. 20.6% DES, p  0.009; vs. 24.6% BMS, p 
0.001) were signiﬁcantly lower with E-ZES. The E-ZES was associated with signiﬁcantly lower target
lesion revascularization (TLR) compared with BMS (7.4% vs. 16.3%, p  0.001) but similar to compar-
ator DES (7.4% vs. 8.1%, p  0.63). Despite higher TLR in the ﬁrst year with E-ZES compared with
DES, between 1- and 5-year follow-up, rates of cardiac death/MI, TLR, and deﬁnite/probable stent
thrombosis were signiﬁcantly lower with E-ZES.
Conclusions Over 5 years, signiﬁcant differences in cardiac death/MI and composite endpoints fa-
vored treatment with E-ZES over comparator BMS and DES. Rates of clinical restenosis and safety
events, including stent thrombosis beyond the ﬁrst year of revascularization, remain stable with
E-ZES, leading to signiﬁcant differences compared with ﬁrst-generation DES. (J Am Coll Cardiol Intv
2013;6:504–12) © 2013 by the American College of Cardiology Foundation
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505An important focus of early drug-eluting stent (DES) trials
involved the comparison of angiographic surrogate indexes
related to the anti-proliferative effect of DES (1–3) and its
correlation with intermediate-term (e.g., 9- to 12-month)
revascularization rates (4–6). Despite variance in angiographic
easures between DES, differences in clinical outcomes were
ess distinct, and the clinical phenotype of DES was considered
“class effect” (7). In comparison with late lumen loss or
ngiographic restenosis as endpoints, more contemporary trials
irected toward patient-oriented clinical outcomes have identified
See page 513
emerging differences in late efficacy and safety events be-
tween DES that are less closely linked to early measures
(8–10).
The ENDEAVOR zotarolimus-eluting stent (E-ZES)
clinical trial program constituted 5 registration studies that
included patients treated with E-ZES, bare-metal stents
(BMS), or first-generation sirolimus- and paclitaxel-eluting
stents (3,11–15). Among randomized trials with protocol-
mandated angiographic surveillance, E-ZES was associated
with significantly higher angiographic late lumen loss and
binary restenosis compared with alternative DES yet lower
restenosis and repeat revascularization versus BMS. As part
of planned 5-year follow-up, an important objective is not
only to compare events relative to treatment assignment but
also to determine whether the early observation of greater
neointimal hyperplasia with E-ZES is associated with pro-
gression of adverse events beyond the initial study reports.
Therefore we evaluated, as a final report, the combined
late-term safety and efficacy outcomes among patients
enrolled in the ENDEAVOR trials, comparing E-ZES,
BMS, and first-generation DES patient cohorts over the
entire 5-year study period.
Methods
Overview of trials and study population. The Endeavor
tent clinical trials program constitutes a series of a prospec-
ive, international trials enrolling patients with symptomatic
schemic heart disease due to de novo stenotic lesions
50% angiographic diameter stenosis by visual estimate) in
ative coronary arteries (3,11–15). Study population sizes/
rial were: ENDEAVOR I (n  100); ENDEAVOR II
n  1,194); ENDEAVOR II Continued Access Study
n  296); ENDEAVOR III (n  436); ENDEAVOR IV
n  1,548); and ENDEAVOR pharmacokinetic/
harmacodynamic study (n  42). Further detail with
egard to enrollment criteria and study methods has been
reviously reported. In all trials, patients were excluded if
hey experienced recent (72 h) myocardial infarction
MI), underwent prior stent placement within the target
essel or any other vessel within 30 days of the indexrocedure, or had any general contraindication to the
evascularization procedure and routine pharmacological
herapies. Principal angiographic exclusion criteria were a
eft ventricular ejection fraction 30%, stenosis 40%
lsewhere in the target vessel (other than the target lesion),
nvolvement of a sidebranch 2.0 mm in diameter,
nprotected left main coronary disease, total occlusions,
nd Thrombolysis in Myocardial Infarction flow grade
2 in the treatment vessel. The studies (with pre-
pecified follow-up through 5 years) were approved by
he institutional review boards or ethics committees at
ach enrolling site, and consecutive, eligible patients
igned written informed consent before the interven-
ional procedure.
This analysis included all pa-
ients enrolled in these trials who
ere treated with the E-ZES, a
obalt-based alloy stent with a
hosphorylcholine polymer and
otarolimus dose concentration of
0 g/mm stent length; a cobalt
lloy bare-metal stent (Driver,
edtronic, Santa Rosa, Califor-
ia); a sirolimus-eluting stent
Cypher, Cordis Corporation,
ridgewater, New Jersey); or a
aclitaxel-eluting stent (Taxus,
oston Scientific Corporation,
atick, Massachusetts). The
-ZES were available, depending
pon the trial, in diameters rang-
ng from a minimum of 2.25 mm
o a maximum 3.5 mm and in
engths from 9 to 30 mm. Before
evascularization, all patients re-
eived treatment with aspirin and
lopidogrel per protocol, and all
atients were treated with a min-
mum of 3 months of dual anti-
latelet therapy (DAPT), except
or those in the ENDEAVOR IV trial, in which patients
eceived a minimum of 6 months of DAPT to maintain
linding of DES assignment with the comparator
aclitaxel-eluting stent. Aspirin therapy was recom-
ended for an indefinite time period.
Study endpoints and deﬁnitions. The primary objective of
this pooled analysis was to evaluate late-term safety and
outcomes among patients treated with E-ZES and to
compare these events with a parallel cohort of patients
treated with either BMS or alternative DES. Clinical safety
outcomes included all-cause and cardiac death, MI, stroke,
and stent thrombosis (ST) (per Academic Research Con-
sortium criteria [16]) annually through 5-year follow-up.
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
E-ZES  ENDEAVOR
zotarolimus-eluting stent(s)
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularization
ZES  zotarolimus-eluting
stent(s)Cardiac death was considered as any fatal event not attrib-
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506utable to a noncardiac cause. Myocardial infarction was
defined as a creatine kinase elevation 2 above the upper
imit of normal with any associated elevation in the creatine
inase myocardial band or the development of new patho-
ogical Q waves in at least 2 contiguous electrocardiographic
eads. An independent clinical events committee adjudi-
ated all clinical endpoints, and except for the single-arm
NDEAVOR I trial and ENDEAVOR II continued
ccess registry, reviewers were blinded to the treatment
ssignment of the patient.
Statistical methods. From the individual trials, patients
were analyzed for all safety and efficacy endpoints on the
basis of the intent-to-treat principle. Baseline characteristics
of study patients were summarized in terms of frequencies
and percentages for categorical variables and by means with
SDs for continuous variables. Categorical variables were
compared by Fisher’s exact test or the Cochran-Mantel-
Haenszel test, and continuous variables were compared by
2-sample t test or analysis of variance. Cumulative event-
free survival was summarized as Kaplan-Meier estimates. A
p value of 0.05 was established as the level of statistical
significance for all tests. All analyses were performed with
SAS software (version 8.2, SAS Institute Inc., Cary, North
Carolina).
Results
As part of 5 registration trials involving patients undergoing
percutaneous revascularization with E-ZES (n  2,132),
alternative DES (n  888; 775 paclitaxel-eluting stent
PES], 113 sirolimus-eluting stent [SES]), and BMS (n 
96), clinical follow-up through 5 years was complete for
5.1% of patients (95.4%, 93.1%, and 97.2% of the E-ZES,
rst-generation DES, and BMS cohorts, respectively).
verall, 39% of patients underwent protocol-mandated
ngiographic surveillance before 1 year. Baseline clinical and
ngiographic characteristics were generally similar across
reatment groups, although modest but statistically signifi-
ant differences were observed (Table 1). Overall, the
verage age of the study population was 63 years, and the
revalence of diabetes was 26%, prior MI was 23%, and
rior coronary revascularization was 46%. Treatment in-
olving the left anterior descending artery as the target
essel was most common, and 70% of lesions were charac-
erized as type B2/C. The presence of diabetes was greatest
n the first-generation DES cohort, intermediate in the
-ZES group, and least common in the BMS group. In the
-ZES cohort, the mean  SD reference vessel diameter
nd lesion length were 2.73  0.47 mm and 14.17  6.10
m, respectively, and did not statistically differ from first-
eneration DES or BMS comparator groups.
Although similar at 30 days, late-term adherence to
APT varied considerably across treatment groups and wasighest among those receiving first-generation DES andowest among patients treated with BMS at 1 and 5 years
Fig. 1). Compared with first-generation DES, treatment
ith DAPT among E-ZES patients was significantly lower
t 1 year and approximately one-half that of first-generation
ES annually thereafter.
By 5 years, all-cause mortality (7.4% vs. 9.6%, p 0.057)
Table 2) and definite/probable stent thrombosis (0.9% vs.
.8%, p  0.178) (Fig. 2A) tended to be lower among
atients treated with E-ZES compared with first-
eneration DES. However, the cumulative incidence of MI
3.3% vs. 5.8%, p  0.002) and combined cardiac death/MI
ere significantly lower with E-ZES, also resulting in
ignificant differences between groups with regard to com-
osite endpoints of major adverse cardiac events (MACE)
nd target vessel failure. Overall target lesion revasculariza-
ion (TLR) was similar between cohorts (7.4% E-ZES vs.
.1% alternative DES, p  0.63).
In comparison with BMS, overall 5-year survival and
ccurrence of definite/probable stent thrombosis were sim-
lar for E-ZES patients (Fig. 2A, Table 2). A trend toward
ower MI with E-ZES was observed (3.3% vs. 4.8%, p 
.07), and combined with a more than 50% reduction in
LR (7.4% vs. 16.3%, p  0.001), this variance contributed
o significant differences in composite safety and efficacy
ndpoints favoring E-ZES.
When late-term events were examined for patients with
vent-free survival beyond the first year of index revascular-
zation and through 5 years, comparisons between E-ZES
nd first-generation DES followed a pattern similar to
verall 5-year outcomes, except for repeat revascularization
Fig. 3, Table 2). Specifically, the occurrences of late MI
1.1% vs. 3.2%, p  0.001) and combined cardiac death/MI
ere significantly lower with E-ZES (Fig. 4). Late stent
hrombosis was also significantly less common with E-ZES,
ompared with first-generation DES (0.31% vs. 1.73%, p 
.001) (Fig. 2B). In contrast to overall 5-year TLR, in a
andmark analysis, subsequent revascularization between 1
nd 5 years was significantly less common with E-ZES,
ompared with PES and SES (2.7% vs. 5.3%, p  0.001)
Fig. 3); in addition to differences in safety events, this
isparity contributed to overall significant differences in late
ACE and target vessel failure. In comparisons of BMS
nd E-ZES, no statistically significant differences in late
afety or efficacy outcomes were identified.
iscussion
In the final 5-year report of registration studies representing
3,616 patients treated in the E-ZES clinical trials program,
significant differences in the cumulative incidence of cardiac
death/MI, stent thrombosis, and composite safety and
efficacy endpoints favored treatment with E-ZES over
first-generation comparator DES. Despite consistently
higher angiographic late lumen loss with E-ZES compared
ry inter
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507with SES and PES (3,15), rates of clinical restenosis and
thrombotic events beyond the initial year of index revascu-
larization remained relatively stable with E-ZES, also lead-
ing to significant differences in safety and efficacy outcomes.
In contrast, E-ZES was associated with a more than halving
in repeat revascularization, a trend toward lower MI, and no
difference in stent thrombosis over 5 years versus a compa-
rable patient group treated with BMS.
Since initial reports associating late stent thrombosis and
restenosis with delayed hypersensitivity and neoatherosclerosis
among first-generation DES (17–21), development of
newer DES that effectively suppress neointimal hyperplasia
yet enhance biocompatibility, promote vessel healing, and
restore vasomotor function after percutaneous coronary
intervention has become an increasing focus. In particular,
long after dissipation of anti-proliferative drug, the persis-
tence of selected durable polymer coatings has been associ-
ated with incomplete endothelialization, expansive vessel
Table 1. Baseline Clinical and Angiographic Characteristics
E-ZES
Patient characteristics
Age, yrs 62.5 10.7 (2,132)
Male 71.5% (1,524/2,132)
Diabetes mellitus 26.1% (555/2,129)
Hypertension 73.0% (1,551/2,126)
Hyperlipidemia 81.2% (1,720/2,118)
History of smoking 49.2% (1,035/2,105)
Prior MI 28.5% (604/2,117)
Prior PCI 26.0% (554/2,130)
Prior coronary bypass surgery 6.7% (143/2,132)
Clinical presentation
Stable angina 40.8% (752/1,843)
Unstable angina 49.3% (909/1,843)
MI 9.9% (182/1,843)
CCS class III/IV 43.0% (869/2,022)
Angiographic characteristics
Target vessel
Left anterior descending 43.8% (931/2,124)
Left circumﬂex 24.4% (518/2,124)
Right coronary 31.8% (675/2,124)
Type B2/C lesion 71.4% (1,516/2,124)
Number of diseased vessels (50% stenosis)
Single 58.8% (1,253/2,131)
Double 26.7% (569/2,131)
Triple 14.5% (309/2,131)
Left ventricular ejection fraction, % 58.9 10.9 (1,841)
Reference vessel diameter, mm 2.7 0.5 (2,124)
Lesion length, mm 14.2 6.1 (2,110)
Minimum lumen diameter, mm 0.9 0.4 (2,124)
Diameter stenosis, % 67.5 12.4 (2,124)
Values are mean SD (N) or % (n/N). *Comparison Endeavor zotarolimus-eluting stents (E-ZES) ve
CCS Canadian Cardiovascular Society; MImyocardial infarction; PCI percutaneous coronaremodeling, neoatherosclerosis, and delayed arterial healingassociated with chronic inflammation (20–24). The E-ZES
is constructed from a thin-strut cobalt alloy platform and
biomimetic phosphorylcholine polymer that might permit
more rapid and complete endothelial coverage and recovery
of vasomotor reactivity similar to that observed with BMS
and distinct from alternative DES (25–29). Unlike other
polymer-based DES, however, the more rapid elution
kinetics of the rapamycin derivative zotarolimus (95%
within 14 days of implantation) also permit greater angio-
graphic late lumen loss compared with other DES yet less
than conventional BMS (3,12,15).
Although assessment of late safety events after DES
revascularization has become commonplace in clinical
trials, only recently have temporal patterns in progression
of luminal loss and TLR been examined. Among patients
treated with SES, for example, progression of angio-
graphic in-stent late lumen loss and TLR beyond inter-
mediate follow-up has been described as a “late catch-up”
1st-Gen DES p Value* BMS p Value†
.3 11.1 (888) 0.052 61.9 10.5 (596) 0.226
0.2% (623/888) 0.481 75.3% (449/596) 0.070
0.2% (268/888) 0.022 22.2% (132/595) 0.055
1.5% (724/888) 0.001 68.2% (403/591) 0.026
5.0% (755/888) 0.012 76.9% (455/592) 0.023
2.3% (547/878) 0.001 35.2% (207/588) 0.001
2.9% (199/870) 0.001 41.5% (247/595) 0.001
7.9% (248/888) 0.278 18.0% (107/594) 0.001
8.3% (74/888) 0.122 4.9% (29/596) 0.106
0.504 0.514
0.8% (359/707) 33.3% (181/543)
6.8% (331/707) 50.8% (276/543)
2.4% (17/707) 15.8% (86/543)
9.0% (344/882) 0.050 48.9% (262/536) 0.016
0.364 0.173
1.3% (366/887) 47.6% (281/591)
6.4% (234/887) 21.2% (125/591)
2.4% (287/887) 31.3% (185/591)
9.1% (613/887) 0.219 79.0% (467/591) 0.001
0.369 0.030
7.4% (509/887) 62.9% (375/596)
6.6% (236/887) 26.3% (157/596)
6.0% (142/887) 10.7% (64/596)
.3 10.2 (863) 0.001 60.8 11.9 (453) 0.002
.7 0.5 (887) 0.350 2.8 0.5 (591) 0.127
.9 6.3 (885) 0.359 14.4 5.7 (588) 0.456
.9 0.4 (887) 0.015 0.8 0.4 (591) 0.004
.0 13.0 (887) 0.003 69.6 11.0 (591) 0.001
g-eluting stents (DES); †comparison E-ZES versus bare-metal stents (BMS).
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508the ISAR TEST 2 (Intracoronary Stenting and Angio-
graphic Results: Test Efficacy of Three Limus-Eluting
Stents) trial that included serial angiographic follow-up
(32), accrual of binary angiographic restenosis between 1
and 2 years was more common for SES compared with
E-ZES, corresponding to higher incident TLR between
1 and 2 years for SES. Similarly, erosion of angiographic
luminal dimensions and progression of late TLR have
also been described with paclitaxel- and everolimus-
eluting stents (30,34). In the ENDEAVOR III and IV
trials, despite numerically higher TLR at time of the
primary endpoint with E-ZES, accrual of late TLR was
numerically but not significantly more common with SES
and PES compared with E-ZES beyond the initial period
of angiographic surveillance (33,35). In comparisons of
these outcomes observed with PES and SES with a
broader E-ZES population in the present study, the
difference in late TLR achieved statistical significance but
notably not in comparison with BMS.
Altogether, these results support the effectiveness of
E-ZES over long-term follow-up and are particularly sug-
gestive of their relative effectiveness compared with first-
generation DES, especially beyond the period of angio-
graphic surveillance and despite initial angiographic late loss
that is nearly 2 to 3 times higher than comparator DES.
The stability in TLR beyond 1 year was consistently
observed across individual studies; proportionately, in all
ENDEAVOR trials, TLR beyond the first year represented
less than one-half of cumulative 5-year repeat revasculariza-
tion versus more than one-half with SES and PES (in
ENDEAVOR III and IV). As such, late outcomes are likely
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Figure 1. DAPT Adherence Through 5 Years
Dual antiplatelet therapy (DAPT) use for Endeavor zotarolimus-eluting
stents (E-ZES), ﬁrst-generation (1st Gen) drug-eluting stents (DES), and
bare-metal stents (BMS) at 30 days (p  NS) and annually through 5 years
post stent implantation (p  0.001 for E-ZES vs. 1st Gen DES and E-ZES vs.
BMS for each year).more representative of spontaneous, clinically driven events Zthan a result of protocol-mandated angiographic surveil-
lance. In this regard, early angiographic measures might be
less predictive of late-term efficacy, and a clinical thresh-
old might exist for angiographic measures below which
the risk of repeat revascularization is similar for DES,
unless driven by scheduled angiography (36,37). As an
example, in the ENDEAVOR III and IV trials, qualify-
ing angiographic binary restenosis (i.e., 50% stenosis)
was higher with ZES compared with SES and PES,
respectively, yet a similar proportion of patients were
identified with an in-segment percentage diameter ste-
nosis of 70% or greater (26.5% ZES vs. 25.0% SES, p 
.00; 37.8% ZES vs. 39.6% PES, p  0.47). Furthermore,
estenosis risk was dissociated from clinical endpoints of death
nd MI that instead favored treatment with E-ZES, contest-
ng the notion that less favorable early angiographic surrogates
f efficacy accurately predict important clinical events.
Safety-related outcomes in the present study for
-ZES are also consistent within the individual trials in
ddition to external investigation. Cumulative event-free
urvival from all-cause death and stent thrombosis tended
o be lower with E-ZES compared with first-generation
ES, and overall cardiac death/MI and very late stent
hrombosis were significantly less common. These re-
ults, particularly those related to very late stent throm-
osis, are especially remarkable against the background of
ess frequent adherence to DAPT among E-ZES patients
fter the first year. Whether biocompatibility of the
hosphorylcholine polymer or more permissive neointi-
al hyperplasia with E-ZES allow less intensive anti-
latelet therapy is speculative, although adherence to
spirin and thienopyridine treatment for durations 12
onths after E-ZES revascularization has been associated
ith favorable long-term outcomes (38). Through 5-year
ollow-up in the ENDEAVOR IV trial, a significant
ifference in cardiac death and MI in addition to very late
tent thrombosis emerged favoring treatment with
-ZES versus PES (35). Over 5-year follow-up in the
NDEAVOR III trial, differences in mortality and MI
lso developed favoring E-ZES compared with SES with
o statistically significant difference in TLR (33). Among
ess selected patient populations as studied in the SORT
UT III (Efficacy and safety of zotarolimus-eluting and
irolimus-eluting coronary stents in routine clinical care)
rial (n  2,332), modest but statistically significant
ifferences in all-cause mortality, TLR, and MI instead
avored treatment with SES at 18-month follow-up (39);
owever, at 3 years, these differences no longer were
ignificant, and the occurrence of very late definite stent
hrombosis was in fact significantly lower with E-ZES
40). In another inclusive randomized trial comparing
ES, PES, and SES, 1-year MACE outcomes did not
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509differ significantly between SES and ZES groups (41),
although the significantly lower MACE with ZES com-
pared with PES in that study is generally consistent with
the lower incidence of target vessel failure observed in the
5-year follow-up of the ENDEAVOR IV trial (35).
Study limitations. Nonetheless, despite similarity of en-
ollment criteria and consistency of ZES outcomes in this
arger pooled analysis, the sample size estimates for
ndividual trials were intended to evaluate angiographic
r composite clinical endpoints, and the overall low event
ates described in this investigation still limit the statis-
ical power for comparison of component endpoints, such
Table 2. Clinical Outcomes
E-ZES
Through 5 years (n  2,033)
Death (all) 7.4% (151)
Cardiac death 2.8% (57)
MI (all) 3.3% (67)
Q-wave 0.5% (10)
Non–Q-wave 2.9% (58)
Cardiac death or MI 5.8% (117)
Target lesion revascularization 7.4% (151)
Target vessel revascularization 13.1% (266)
Nontarget lesion, target vessel revascularization 7.1% (144)
Target vessel failure 17.1% (348)
Major adverse cardiac events 16.1% (328)
Stent thrombosis (ARC)
Deﬁnite 0.7% (15)
Probable 0.2% (4)
Possible 1.8% (37)
Deﬁnite or probable 0.9% (19)
Any 2.8% (56)
1–5 years (n  1,961)
Death (all) 6.6% (129)
Cardiac death 2.2% (43)
MI (all) 1.1% (21)
Q-wave 0.3% (5)
Non–Q-wave 0.9% (17)
Cardiac death or MI 3.1% (60)
Target lesion revascularization 2.7% (52)
Target vessel revascularization 6.1% (120)
Nontarget lesion, target vessel revascularization 4.0% (79)
Target vessel failure 8.6% (169)
Major adverse cardiac events 9.6% (188)
Stent thrombosis (ARC)
Deﬁnite 0.2% (4)
Probable 0.1% (2)
Possible 1.5% (29)
Deﬁnite or probable 0.3% (6)
Any 1.8% (35)
Values are % (n). *Comparison E-ZES versus DES; †comparison E-ZES versus BMS.
ARC Academic Research Consortium; other abbreviations as in Table 1.s stent thrombosis and mortality. Therefore, these aesults with regard to such endpoints should be considered
xploratory rather than definitive and serve as a foundation
or ongoing comparative investigation. Even in such studies,
here are some consistencies with the present results; in the
ROTECT (Patient Related Outcomes with Endeavor
ersus Cypher Stenting Trial), for example, although overall
-year definite or probable stent thrombosis was similar
etween E-ZES and SES, very late (1 year) stent throm-
osis was significantly lower with E-ZES (0.3% vs. 1.1%,
 0.001) (42). Although this patient level overview of
rials with homogenous inclusion and exclusion require-
ents, comparisons across stent types nevertheless represent
st-Gen DES p Value* BMS p Value†
(n  826) (n  582)
9.6% (79) 0.057 7.6% (44) 0.057
3.6% (30) 0.235 3.6% (21) 0.235
5.8% (48) 0.003 4.8% (28) 0.072
0.7% (6) 0.455 1.2% (7) 0.065
5.1% (42) 0.005 3.6% (21) 0.310
8.8% (73) 0.003 8.4% (49) 0.017
8.1% (67) 0.625 16.3% (95) 0.001
4.8% (122) 0.297 20.1% (117) 0.001
9.3% (77) 0.044 6.2% (36) 0.491
0.9% (173) 0.026 24.4% (142) 0.001
0.6% (170) 0.009 24.6% (143) 0.001
1.2% (10) 0.389 1.5% (9) 0.063
0.6% (5) 0.248 0.2% (1) 0.918
2.7% (22) 0.388 2.2% (13) 0.207
1.8% (15) 0.178 1.7% (10) 0.076
4.5% (37) 0.099 4.0% (23) 0.048
(n  789) (n  570)
8.7% (69) 0.051 7.0% (40) 0.654
3.2% (25) 0.136 3.0% (17) 0.258
3.2% (25) 0.001 0.9% (5) 0.714
0.6% (5) 0.151 0.4% (2) 0.689
2.5% (20) 0.001 0.5% (3) 0.441
6.0% (47) 0.001 3.9% (22) 0.320
5.3% (42) 0.001 3.7% (21) 0.166
9.8% (77) 0.001 7.2% (41) 0.293
6.2% (49) 0.014 4.0% (23) 0.927
4.2% (112) 0.001 9.8% (56) 0.313
5.6% (123) 0.001 11.1% (63) 0.252
1.1% (9) 0.008 0.2% (1) 0.815
0.6% (5) 0.069 0.2% (1) 1.000
2.2% (17) 0.511 1.8% (10) 0.215
1.8% (14) 0.002 0.4% (2) 0.652
3.9% (31) 0.009 2.1% (12) 0.2231
1
2
2
1
1composite of randomized and indirect evaluation and
s for E
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510might introduce confounding not resolved by randomiza-
tion alone. Furthermore, these findings were observed
among patients undergoing elective percutaneous revascu-
larization with relatively simple to moderate lesion complex-
ity, and thus the results cannot be extended to high clinical
risk and complex lesion patient populations. Whether un-
blinding to DES type after endpoint ascertainment also
introduced treatment bias that could influence outcomes is
uncertain. However, less frequent prescription of DAPT in
the E-ZES cohort might pose higher risk for late throm-
botic events, and awareness of treatment with a higher late
lumen loss stent might lower the threshold for repeat
angiography and intervention, yet in fact the opposite
direction in clinical events was observed. Finally, given the
frequent performance of surveillance angiography in the
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Figure 2. Cumulative Incidence of Definite and Probable ST
Cumulative incidence curves of (A) Academic Research Consortium-deﬁned de
demic Research Consortium-deﬁned deﬁnite and probable ST from 1 to 5 yearENDEAVOR trials, it is plausible that temporal differencesin late TLR between DES are the result of a frame-shift of
E-ZES–related TLR to earlier time points. Most TLR
events, however, were clinically rather than angiographically
driven, and in the comparative trials with first-generation
DES, equal proportions of patients in each treatment group
underwent follow-up angiography.
Conclusions
In the context of comparison with first-generation DES and
BMS, these results support the early- and late-term safety
and efficacy after percutaneous revascularization with
E-ZES. In the final 5-year report of patients enrolled in the
E-ZES clinical trials program, treatment with E-ZES was
associated with statistically significant reductions in cardiac
3 y 4 y 5 y
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and probable stent thrombosis (ST) from 0 to 5 years and (B) very late Aca-
-ZES, 1st Gen DES, and BMS. Abbreviations as in Figure 1.e After 
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511a pooled cohort of patients receiving first-generation SES
and PES. Despite higher angiographic restenosis with
E-ZES, the cumulative need for repeat revascularization
was similar between DES types. Over late-term follow-up,
important differences emerged favoring E-ZES with regard
to very late stent thrombosis and TLR. In comparison with
BMS, treatment with E-ZES demonstrated durable and
significant reductions in repeat revascularization with no
safety differences observed. Overall, these findings are con-
sistent with those from additional recent studies identifying
differential temporal progression of angiographic measures
and clinical events among DES and challenge earlier
models relating early angiographic measures to long-term
outcomes.
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Figure 3. Landmark Analysis of TLR From 0 to 1 and 1 to 5 Years
Landmark analysis of target lesion revascularization (TLR) showing cumula-
tive incidence of TLR from 0 to 1 year and from 1 to 5 years for E-ZES, 1st
Gen DES, and BMS. Abbreviations as in Figure 1.
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Figure 4. Landmark Analysis of CDMI From 0 to 1 and 1 to 5 Years
Landmark analysis of cardiac death and myocardial infarction (CDMI) show-
ing cumulative incidence of CDMI from 0 to 1 year and from 1 to 5 years
for E-ZES, ﬁrst-generation DES, and BMS. Abbreviations as in Figure 1.REFERENCES
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